Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT 8225

Next Previous
Drug Profile

FT 8225

Alternative Names: FT-8225

Latest Information Update: 28 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FORMA Therapeutics
  • Class Hepatoprotectants
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-alcoholic steatohepatitis

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
  • 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
  • 01 Aug 2019 Forma Therapeutics has patent protection for FT 8225 and its use for treating nonalcoholic steatohepatitis in World before August 2019 (Forma Therapeutics pipeline, August 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top